Related Experiment Video

Updated: Aug 7, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Targeting the c-Met signaling pathway in cancer

Benedetta Peruzzi1, Donald P Bottaro

  • 1Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 17, 2006
PubMed

Insights

Hepatocyte growth factor (HGF) binding to c-Met receptor tyrosine kinase (TK) drives cell growth and tissue repair but also cancer progression. Targeting HGF/c-Met signaling offers new anticancer drug development strategies.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Drug Discovery

Background:

  • Hepatocyte growth factor (HGF) interacts with the c-Met receptor tyrosine kinase (TK).
  • HGF/c-Met signaling regulates vital cellular processes like growth, migration, and differentiation.
  • Dysregulated HGF/c-Met signaling is implicated in oncogenesis, tumor progression, and metastasis.

Purpose of the Study:

  • To review the role of HGF/c-Met signaling in normal physiology and cancer.
  • To explore therapeutic strategies targeting the HGF/c-Met pathway for cancer treatment.

Main Methods:

  • Review of preclinical and clinical studies on HGF/c-Met signaling.
  • Analysis of drug development approaches targeting ligand-receptor interaction, TK catalytic activity, and intracellular effector interactions.

Main Results:

  • HGF/c-Met pathway is crucial for development, homeostasis, and regeneration.
  • Aberrant HGF/c-Met signaling promotes cancer growth, invasion, and metastasis.
  • Preclinical drug candidates targeting HGF/c-Met have shown promise.

Conclusions:

  • Targeting HGF/c-Met signaling represents a viable strategy for anticancer drug development.
  • Three main therapeutic avenues exist: blocking ligand-receptor binding, inhibiting TK activity, or disrupting intracellular interactions.
  • Clinical trials are underway for drugs targeting this pathway.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...